Expression data from skin biopsies in patients with systemic sclerosis treated with beta-catenin inhibitor (C82) and placebo

Wnt signaling pathway is thought to have a role in skin fibrosis in Systemic slcerosis. This Randomized, Placebo-Controlled trial examines the effect of beta catenin inhibition on skin expression. We used microarrays to explore gene expression changes in the C82 trial Patietns with diffuse cutaneous systemic sclerosis had biopsis before treatment and at day 28.